Nearly two years after its spin-out from bluebird, 2Seventy is slowing in-house R&D and leaning on partners to conserve cash while BMS-partnered Abecma regains its competitive footing.

An early stage CAR-T trial in acute myeloid leukemia has been halted after a patient death, adding to 2Seventy’s difficulties in growing sales of its myeloma treatment Abecma.

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.